Skip to content

Sentinel lymph nodes mapping in ovarian cancer

Sentinel lymph nodes mapping in ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091611
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarain

Interventions

Experimental Group:All the patients were injected with methylene blue into the ovarian cortex, uterine horns and infundibulopelvic ligaments by the surgeon1

Sponsors

Fourth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Women 18-80 years of age who agreed to participate in the trial and provided written informed consent. 2. Ovarian cancer was confirmed by frozen pathology before or during operation. 3. According to Suidan or Fagotti score, it is expected to be feasible to perform comprehensive staging of early ovarian cancer or R0 cytoreductive surgery for advanced ovarian cancer. 4. After clinical evaluation, the patient could tolerate anesthesia and surgery. 5. Voluntary participation in the trial (written informed consent).

Exclusion criteria

Exclusion criteria: 1. Suspected adnexal mass showed benign results by intraoperative frozen pathology. 2. Allergic reactions or other adverse reactions to previous methylene blue use. 3. Pregnancy. 4. Previous pelvic and abdominal radiotherapy history. 5. Previous history of lymphoma. 6. Previous history of lymphadenectomy. 7. Combined with other malignant tumors. 8. Patients who are not suitable for anesthesia or surgery after evaluation. 9. The investigator believes that the patients have other factors that may affect the study results and interfere with their participation in the whole study process, including past or existing physical conditions, treatment or laboratory abnormalities, etc. Or the investigator believes that participation in the study would not be in the best interest of the patient.

Design outcomes

Primary

MeasureTime frame
Sentinel lymph node metastasis Detection rate;Surgical Complications;

Secondary

MeasureTime frame
Distribution of positive sentinel lymph nodes;

Countries

China

Contacts

Public ContactZhang Zhengmao

Fourth Hospital of Hebei Medical University

1356606@vip.sina.com+86 139 3321 9926

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026